OTCM
BFMHF
Market cap544mUSD
, Last price
USD
Name
Beauty Farm Medical & Health Industry Inc
Chart & performance
P/E
—
P/S
—
EPS
1.28
Vol. 1Y
—
Shs. 5Y
0.11%
Rev. 5Y
14.82%
Div Yld LY
—
Div Yld TTM
—
Revenues
3.00b
+16.65%
Net income
318m
+39.00%
CFO
999m
+25.42%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beauty Farm Medical and Health Industry Inc., established in 1993 and based in Shanghai, People's Republic of China, delivers comprehensive beauty and health management services across China. Its diverse offerings encompass traditional beauty treatments; advanced aesthetic medical services, including non-surgical options like energy-based therapies and injections, as well as surgical procedures; and specialized subhealth assessment and intervention programs. As of June 30, 2022, the company operated a network of 352 stores under its BeautyFarm, Palaispa, Neology, and CellCare brands, with 177 being directly owned and 175 franchised.
Key people
Yang Li
Executive Chairman of the Board · since 2022
Songyong Lian
Executive Vice Chairman of the Board and Chief Executive Officer · since 2022
Siu Ying Sarah Kwok
Joint Company Secretary · since 2022
Min Zhou
Chief Financial Officer, Joint Company Secretary · since 2021
Non-Executive Director · since 2025
Jiaqi Geng
Non-Executive Director · since 2022
Tenghe Hu
Non-Executive Director · since 2024
Fangyu Li
Non-Executive Director · since 2022
Non-Executive Director · since 2025
Mingchao Fan
Non-Executive Independent Director · since 2022
Hua Jiang
Non-Executive Independent Director · since 2022
Teng Liu
Non-Executive Independent Director · since 2022
Legal address
Floor 4, Willow House, Cricket Square
Grand Cayman KY1-9010
KY
Grand Cayman KY1-9010
KY
Headquarters
上海市虹口区东大名路1089号12层1206单元
虹口区, SH 200080
CN
虹口区, SH 200080
CN
Other language
Beauty Farm Medical and Health Industry Inc.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||